Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773 · View on ClinicalTrials.gov ↗
Study Summary
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor has decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for up to 3 years or up to 5 years, depending on when they start the study.
Conditions Studied
Interventions
- DRUG Avacincaptad pegol (ACP)
Study Locations (20)
Florida
- Florida Eye Clinic — Altamonte Springs
- Advanced Retina Institute — Bonita Springs
- University of Miami — Coral Gables
- Retina Care Specialists — Palm Beach Gardens
- Eye Physicians of Pinellas PA dba Eye Institute of West Florida — Tampa
- Retina Specialists of Tampa — Wesley Chapel
California
- The Retina Partners — Encino
- Harvard Eye Associates — Laguna Hills
- Retina Consultants of Southern CA — Redlands
- Retinal Consultants Medical Group Inc — Sacramento
- Retina Macula Institute — Torrance
Arizona
- Phoenix Retina Clinical Trials, LLC — Phoenix
- Retinal Consultants of AZ — Phoenix
- Retina Macula Institute of Arizona — Scottsdale
Colorado
- Rocky Mountain Lions Eye Institute — Aurora
- Retina Consultants of Southern Colorado — Colorado Springs
- Colorado Retina Associates, PLLC — Lakewood
Connecticut
- Coastal Eye Surgeons — Greenwich
Georgia
- Southeast Retina Center, P.C. — Augusta
Illinois
- University Retina and Macula Associates, P.C. — Oak Forest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2030-01-31 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06779773
The ClinicalTrials.gov registry entry for NCT06779773 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 172 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Geographic Atrophy appearing as the primary indexed condition, and to 1 intervention — of which Avacincaptad pegol (ACP) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06779773 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06779773 about?
NCT06779773 is a clinical study titled "A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy". This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form ...
What is the current status of trial NCT06779773?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-01-22. Estimated completion is 2030-01-31.
What conditions does trial NCT06779773 study?
This clinical trial studies the following conditions: Geographic Atrophy, Macular Degeneration. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06779773?
The interventions under investigation include: Avacincaptad pegol (ACP) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06779773?
This trial is sponsored by Astellas Pharma Global Development, which has 172 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06779773 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.